Innate Pharma S.A. logo
Innate Pharma S.A. IPHA
$ 1.58 1.28%
report update icon

Quarterly report 2025-Q4
added 05-06-2026

Innate Pharma S.A. Financial Statements 2025-2011 | IPHA

Annual Financial Statements Innate Pharma S.A.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

126 M 148 M 200 M 236 M 363 M 274 M 431 M - - - - - - - -

Shares

89.6 M 81.1 M 80.5 M 79.6 M 79.5 M 66.9 M 66.9 M - - - - - - - -

Historical Prices

1.41 1.83 2.48 2.96 4.56 4.09 6.44 - - - - - - - -

Net Income

-49.2 M -49.5 M -7.57 M -58.1 M -52.8 M -64 M -20.8 M 3.05 M -48.4 M 12.6 M -6.71 M -19.6 M -2.89 M -3.2 M -6.98 M

Revenue

9 M 20.1 M 61.6 M 57.7 M 24.7 M 69.8 M 85.4 M 94 M 44 M 56.2 M 17.9 M 907 K 12.5 M 10.4 M 11.7 M

Gross Profit

- - - - - - 23.8 M - 32.6 M 56.2 M 17.9 M -11.2 M 4.89 M 3.51 M 10.1 M

Operating Income

-54 M -51.6 M -12.7 M -57.4 M -47.8 M 1.08 M 1.58 M 5.15 M -40 M - - - - - -

Interest Expense

440 K 566 K 640 K 288 K 312 K 341 K 204 K 102 K 113 K - - - - - -

EBITDA

-54 M -51.6 M -12.7 M -57.4 M -47.8 M 1.08 M 1.58 M 5.15 M -40 M 7.76 M -10.6 M -17.6 M -1.89 M -2.53 M -6.65 M

Operating Expenses

63 M 71.7 M 74.3 M 115 M 72.5 M 68.7 M 83.9 M 87.7 M 84 M 48.6 M 28.7 M 8.76 M 7.66 M 6.88 M 17.7 M

General and Administrative Expenses

19.4 M 19.7 M 18.3 M 22.4 M 25.5 M 31.2 M 40.7 M 18.1 M 15.7 M 8.88 M 5.59 M 12.5 M 10.4 M 9.33 M -

All numbers in EUR currency

Quarterly Income Statement Innate Pharma S.A.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

89.6 M 86.9 M 81.1 M 80.9 M 80.5 M 80.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-49.2 M -21.3 M -49.5 M -24.8 M -7.57 M 1.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

9 M 4.86 M 20.1 M 12.3 M 61.6 M 40.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-54 M -25.4 M -51.6 M -26.3 M -12.7 M -398 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

440 K 229 K 566 K 300 K 640 K 324 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-54 M -25.4 M -51.6 M -26.3 M -12.7 M -398 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

63 M 30.3 M 71.7 M 38.7 M 74.3 M 40.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

19.4 M 9.77 M 19.7 M 9.58 M 18.3 M 9.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Innate Pharma S.A. IPHA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Innate Pharma S.A. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Zoetis Zoetis
ZTS
$ 71.41 2.45 % $ 31.7 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.22 1.09 % $ 20.6 B australiaAustralia
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 12.32 0.57 % $ 10.3 B indiaIndia
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
- - $ 300 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
Otonomy Otonomy
OTIC
- -1.96 % $ 4.68 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
- - $ 857 M usaUSA
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
- -8.44 % $ 3.4 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
- - $ 382 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark